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Abstract 
The differentiation between exudates and transudates is the initial step in 
the analysis of pleural effusion as it often gives an indication of the underlying 
pathophysiology, the differential diagnosis, and the need for forther 
investigations. There are conflicting results concerning the use of biochemical 
parameters in the differentiation of exudates and transudates. In this study, six 
analytes, namely total protein, albumin, total bilirubin, lactate dehydrogenase, 
total cholesterol and triglyceride in pleural fluid and serum were measured and 
their respective pleural fluid to semm ratios were calculated. The optimal cutoff 
values were found out by using the receiver operating characteristic (ROC) curve. 
The traditionally used Light's criteria was found to be applicable in the 
local community. The optimal cutoff values for pleural fluid to semm ratio of 
total protein was 0.55, for lactate dehydrogenase was 0.55 and for pleural fluid 
lactate dehydrogenase level was 200 U/L. The best diagnostic efficiency was 
obtained when the criteria by Costa et al 1995 was used. The optimal cutoffvalue 
for pleural fluid cholesterol level was found to be 1.2 mmol/L and the optimal 
cutofffor pleural fluid lactate dehydrogenase was 200 U/L. Sensitivity of the test 
combination was 92.7% and specificity was 73.3%. The prevalence of exudative 
pleural effusion was 73.2%. Hence, the positive predictive value was 90.5% and 
the negative predictive value was 78.6%. 
xi 
Since exudative effusion formation involves the change in membrane 
permeability of pleural capillaries, it is suspected that there is a concomitant rise 
in high molecular weight proteins in the fluid. Hence the role of protein zone 
electrophoresis in exudative and transudative pleural effusion differentiation was 
explored. The protein zone electrophoresis was found to be as sensitive as 
(97.4%) the Light's criteria in identification of exudates. The specificities were 
similar. Besides, protein zone electrophoresis gave additional qualitative 
information of the nature of the pleural fluid. 
Increased pleural fluid adenosine deaminase (ADA) activity is classically 
associated with tuberculous pleuritis. However, the role of ADA in the 
differentiation of TB and non-TB exudates has not been extensively studied in 
Asia. Local data are absent. This study attempts to set up a rapid and automated 
assay for ADA in pleural fluid and serum and to establish the optimal pleural fluid 
cutoff value for local Chinese population. 
Using ROC plot, the ADA assay was found to have a sensitivity and 
specificity of 93.3% and 89.36% respectively. The area under the ROC curve was 
0.9574 (standard error 二 0.0247). The prevalence of tuberculous pleurisy in the 
test population was 24.19%. Therefore, the positive and negative predictive 
values were 73.68% and 97.67%. The ADA assay was found to be a sensitive and 
specific test that is suitable for the identification of tuberculous pleurisy in the 
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Abstract 
The differentiation between exudates and transudates is the initial step in 
the analysis of pleural effusion as it often gives an indication of the underlying 
pathophysiology, the differential diagnosis, and the need for further 
investigations. There are conflicting results concerning the use of biochemical 
parameters in the differentiation of exudates and transudates. In this study, six 
analytes, namely total protein, albumin, total bilirubin, lactate dehydrogenase, 
total cholesterol and triglyceride in pleural fluid and serum were measured and 
their respective pleural fluid to semm ratios were calculated. The optimal cutoff 
values were found out by using the receiver operating characteristic (ROC) curve. 
The traditionally used Light's criteria was found to be applicable in the 
local community. The optimal cutoff values for pleural fluid to semm ratio of 
total protein was 0.55, for lactate dehydrogenase was 0.55 and for pleural fluid 
lactate dehydrogenase level was 200 U/L. The best diagnostic efficiency was 
obtained when the criteria by Costa et al 1995 was used. The optimal cutoff value 
for pleural fluid cholesterol level was found to be 1.2 mmoVL and the optimal 
cutoff for pleural fluid lactate dehydrogenase was 200 U/L. Sensitivity of the test 
combination was 92.7% and specificity was 73.3%. The prevalence of exudative 
pleural effusion was 73.2%. Hence, the positive predictive value was 90.5% and 
the negative predictive value was 78.6%. 
xi 
Since exudative efftision formation involves the change in membrane 
permeability of pleural capillaries, it is suspected that there is a concomitant rise 
in high molecular weight proteins in the fluid. Hence the role of protein zone 
electrophoresis in exudative and transudative pleural effusion differentiation was 
explored. The protein zone electrophoresis was found to be as sensitive as 
(97.40/0) the Light's criteria in identification of exudates. The specificities were 
similar. Besides, protein zone electrophoresis gave additional qualitative 
information of the nature of the pleural fluid. 
Increased pleural fluid adenosine deaminase (ADA) activity is classically 
associated with tuberculous pleuritis. However, the role of ADA in the 
differentiation of TB and non-TB exudates has not been extensively studied in 
Asia. Local data are absent. This study attempts to set up a rapid and automated 
assay for ADA in pleural fluid and semm and to establish the optimal pleural fluid 
cutoff value for local Chinese population. 
Using ROC plot, the ADA assay was found to have a sensitivity and 
specificity of 93.3% and 89.36% respectively. The area under the ROC curve was 
0.9574 (standard error = 0.0247). The prevalence of tuberculous pleurisy in the 
test population was 24.19%. Therefore, the positive and negative predictive 
values were 73.68% and 97.67%. The ADA assay was found to be a sensitive and 
specific test that is suitable for the identification of tuberculous pleurisy in the 




Pleural effusions occur in the course of a variety of diseases. When the 
mechanical factors influencing the formation or reabsorption of pleural fluid are 
altered, a transudate is formed (Kinasewitz 1997). Decreased plasma oncotic 
pressure or elevated systemic or pulmonary hydrostatic pressure are alterations 
that produce transudates. In contrast, inflammation or other diseases that alter 
the permeability of the pleural surface or that impair the lymphatic drainage 
result in the formation of an exudate. 
A correct diagnosis of the underlying disease is essential for rational 
management. The cause of a pleural effusion is, however, not always easily 
determined. Frequently, it requires the use of different procedures, some of 
which are invasive and can cause complications. Invasive local procedures, such 
as pleural biopsy, are indicated only in patients with exudative pleural effusions. 
Therefore, the first step in the diagnostic work-up of pleural effusions should be 
to classify them as transudates or exudates. If the effusion is a transudate, no 
further local invasive procedures are necessary. Therapy is directed to the 
underlying causes such as congestive heart failure, cirrhosis, or renal failure. 
The pleural effusion resolves itself once the underlying cause has been treated. 
Alternatively, if the effusion proves to be an exudate, a more extensive 
diagnostic investigation is indicated to delineate the cause of the effusion. 
Traditionally, the criteria by Light et al 1972 characterized pleural 
exudate as having one of the following: pleural fluid/serum LDH > 0.6, pleural 
fluid/serum TP > 0.5, and pleural fluid LDH > 2/3'^ ofthe upper limit of normal 
serum LDH (local reference range = 110-230 U/L ). But the results produced by 
Light et al are not always reproducible and the low specificity of the criteria of 
Light et al may lead to unwarranted invasive intervention in up to 20 to 30% of 
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patients with transudates (Romero et al 1993). This is probably due to the 
occurrence of an exudative range of protein levels in the pleural fluid in many 
patients with congestive heart failure. Moreover, an extensive comparison of 
individual analytes in exudate and transudate has not been done and a systematic 
comparison of their sensitivities and specificities is still lacking. 
In the present study, a more extensive comparison of different analytes 
including bilirubin, cholesterol, triglyceride, total protein, lactate dehydrogenase 
and albumin in paired samples of blood and pleural fluid will be done and the 
specificities and sensitivities of their respective ability to differentiate exudate 
from transudate are analysed by using the ROC curve. Optimal cutoff 
concentrations for defining exudate and transudate will be found out. 
In addition, the role of protein electrophoresis in the diagnosis of exudate 
and transudate has not been attempted in great depth. In this project, paired 
semm and pleural fluid samples would be analyzed by protein zone 
electrophoresis to investigate the difference in constituents ofproteins. 
When a tuberculous pleural effusion occurs in the absence of 
radiologically apparent tuberculosis, it may be the sequel of primary infection 6 
to 12 weeks earlier or it may represent reactivation tuberculosis. Differentially 
diagnosing a tuberculous effusion is hence useful in confirming a TB infection 
and in modifying treatment regimes. The diagnosis of tuberculous pleuritis 
depends upon the demonstration of tubercle bacilli in the sputum, pleural fluid, 
or pleural biopsy specimens or granulomas in the pleura. The diagnosis can also 
be established with reasonable certainty by demonstrating that the pleural fluid 
adenosine deaminase level of above 70 U/L in the pleural fluid (Ocana et al 
1983; Fontan et al 1988; Valdes et al 1993). 
Adenosine deaminase is expressed in all mammalian cells and tissues. Its 
major role is the proliferation and differentiation of lymphocytes, especially T 
lymphocytes and it is hence important in the development of immune 
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competence. The measurement of adenosine deaminase is a much faster way to 
diagnose tuberculous pleural effusion than conventional culture techniques and is 
possibly cheaper than Bactec broth culture method and PCR method. Few data 
are available concerning the diagnostic value of ADA in Asian populations in 
which there exists a gross difference of prevalence of tuberculosis as compared 
to the populations whose cut-offs of ADA have been established. Some report 
that Asian patients with tuberculous pleuritis appear to have lower mean levels of 
ADA (Aoki et al 1994; Tamura et al 1988). It is difficult to adopt quoted figures 
because of differences in methodology and calibration and possible ethnic 
difference. To date, local data are not available. In this project, an automated, 
kinetic assay for adenosine deaminase will be set up and cutoff values for 
differentiating tuberculous and non-tuberculous exudates will be established. 
This enables our laboratory and other laboratories in this locality to derive the 




2.1 Production of pleural fluid 
Human pleura is composed of a parietal pleural membrane, the pleural 
space and a visceral pleural membrane. It is now believed that pleural fluid is 
produced at parietal pleura (Miserocchi 1997) and reabsorbed chiefly by the 
parietal lymphatics O^egrini et al 1985, Negrini et al 1994). The systemic 
pleural capillaries are the sites where filtration takes place. The movement of 
fluid between the pleural capillaries and the pleural space is governed by the 
Starling's law of transcapillary exchange. 
Q f = L p • A [ ( Pcap 一 Ppl ) - C^ d ( ^cap - ^pl y— 
Where Qf is the liquid movement; Lp is the filtration coefficient per unit area or 
the hydraulic water conductivity of the membrane; A is the surface area of the 
membrane; P and n are the hydrostatic and oncotic pressures, respectively, of 
the capillary (cap) and pleural (jp\) space; and Gd is the solute reflection 
coefficient for protein, a measure of the membrane's ability to restrict the 
passage of large molecules. 
Both the positive (30 cm H2O) hydrostatic pressure in the parietal pleura 
and the negative pleural pressure (-5 cm H2O) favour the filtration of the fluid 
out of the parietal capillaries. Opposing this hydrostatic pressure is the oncotic 
pressure ofplasma (which is approximately 34 cm H2O). Pleural fluid normally 
present in the pleural spaces contains a small amount of protein which has an 
oncotic pressure of about 5 cm H2O. The net oncotic pressure is 29 cm H2O) 
favouring the movement of fluid into the capillaries. The net gradient is 35-29 = 
6 cm H2O favouring the movement of fluid from the capillaries in the parietal 
pleura to the pleural space (Light 1995). 
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Because the pressure in the visceral pleural capillaries is approximately 6 
cm H2O lower than that in parietal pleural capillaries and the former drains into 
the pulmonary veins, it is thought that the net gradient for movement of fluid 
from the visceral pleural capillaries into the pleural space is close to zero (Light 
1995). 
Although there is a positive pressure gradient for fluid movement out of 
the pleura into the pleural spaces, accumulation of pleural fluid in a healthy 
individual is prevented by the effective fluid clearance by the pleural lymphatics. 
Parietal lymphatics open directly on the parietal pleural surfaces through 
stomata. However, stomata are absent from visceral pleural surfaces. Proteins, 
cells and all other particulate matters are removed from the pleural space by 
these lymphatics in the parietal pleura (Cooray 1949; Courtice and Simmonds 
1949; Burke 1959; Wang 1975). The lymphatics have a considerable reserve for 
removal of pleural fluid. Once the pleural fluid volume exceeds a certain 
threshold, the lymphatics operate at maximum capacity. The capacity for 
lymphatic clearance is 28 times as high as the normal rate of pleural fluid 
formation in those circumstances (Light 1995). Most of the pleural fluid is 
removed by lymphatics draining the lower costal, mediastinal and diaphragmatic 
regions of the pleural cavity (Broaddus et al 1988). 
2.2 Pathophysiology of pleural effusion 
Pleural fluid accumulates when the rate of formation exceeds that 
of reabsorption. Causes of pleural effusions are tabulated in Table 1 • The 
commonest cause of increased pleural fluid formation is increased 
interstitial fluid in the lung. The commonest disease entity within this 
group is congestive heart failure. Very often, congestive heart failure is 
associated with the presence of pulmonary venous hypertension that 
produces alveolar oedema. Increased interstitial pressure results and 
oedema fluid leaks out from the visceral pleural surface into the pleural 
spaces. Fluid accumulates when the entry of fluid overwhelms the 
capacity of the lymphatics in the parietal pleura to remove the 
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Table 1 Causes of pleural effusion 
Increased pleural fluid formation 
Increased interstitial fluid in the lung 
Left ventricular failure, pneumonia, pulmonary embolus 
Increased intravascular pressure in pleura 
Right or left ventricular failure, superior vena caval syndrome. 
Increased pleural fluid protein level 
Decreased pleural pressure 
Lung atelectasis or increased elastic recoil of the lung. 
Increased fluid in peritoneal cavity 
Ascites or peritoneal dialysis 
Disruption of the thoracic duct 
Hypoalbuminaemia 
Decreased pleural fluid absorption 
Obstruction of the lymphatics draining the parietal pleura 
Elevation of systemic vascular pressures 
Superior vena caval syndrome or right ventricular failure 
Rare cause 
Retroperitoneal leakage of urine 
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fluid (Broaddus et al 1990). Elevation of the systemic venous pressure further 
decreases the lymphatic clearance from the pleural space. 
Besides in congestive heart failure, increased interstitial fluid in the lung 
seems to be the predominant mechanism of pleural fluid formation in left 
ventricular failure, pneumonia and pulmonary embolus. 
If the elevated left atrial pressure is transmitted to the right heart, 
systemic venous pressure will also be increased. The elevation of systemic 
venous pressure will increase the filtration of fluid from the parietal capillaries 
and simultaneously decrease lymphatic flow from the pleural cavity by 
increasing the outflow pressure in the thoracic duct (Aukland and Reed 1996). 
Increased intravascular pressure in pleura is predominantly found in right or left 
ventricular failure and superior vena caval syndrome. 
Inflammatory changes that cause alterations in pleural capillary 
permeability will result in protein leakage from capillary plasma to interstitial 
spaces and then to pleural spaces. The resulting rise in oncotic pressure will 
favour pleural fluid formation. Increased pleural fluid protein level occurs with 
increased permeability pulmonary oedema, hemothorax and malignancy, 
tuberculous pleuritis and empyema. 
Decreased pleural pressure in atelectasis resulting from bronchial 
obstruction favours the increased filtration of fluid into the pleural space. On the 
other hand, diseases in which the elastic recoil of the lung is increased tend to 
create a more negative pleural pressure and facilitates pleural fluid formation. 
Another mechanism of pleural fluid formation is fluid leakage from 
defects in the diaphragm. In patients with tense ascites and increased 
intraabdominal pressure, the diaphragm may be stretched, causing microscopic 
defects (Lieberman et al 1966; Kinasewitz 1997). The increased intraperitoneal 
hydrostatic pressure results in a unidirectional fluid flow from peritoneal to 
pleural cavity. Likewise, if the thoracic duct is disrupted, chyle will accumulate 
in the pleural space by the same path of movement. 
In nephrotic syndrome, hypoalbuminaemia leads to a decrease in plasma 
oncotic pressure whereas salt retention produces hypervolemia which causes an 
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increase in hydrostatic pressure. These result in the formation of pleural 
effusion. 
Obstruction of lymphatic drainage by the presence of metastatic 
carcinoma is the predominant factor contributing to the development of 
malignant pleural effusion (Sahn 1997). Since the lymphatics drain into the 
systemic venous circulation, elevation of the pressures in the central veins will 
decrease the lymphatic flow. Cases in point are superior vena caval syndrome or 
right ventricular failure. 
One rarer cause ofpleural effusion formation is retroperitoneal leakage of 
urine that enters the pleural space via the diaphragmatic lymphatics, occurring in 
association with obstruction uropathy, trauma, malignancy, failed kidney biopsy 
and renal transplantation. 
2.3 Separating exudate from transudate 
The traditional criteria of classifying exudate was developed by Light et 
al 1972. The criteria state that exudative pleural effusion meet one or more of 
the following:-
(1) Pleural fluid total protein to serum total protein ratio greater than 0.5; 
(2) Pleural fluid lactate dehydrogenase to semm lactate dehydrogenase ratio 
greater than 0.6; and 
(3) Pleural fluid lactate dehydrogenase level greater than two-third of upper 
limit ofpopulation reference range for serum lactate dehydrogenase. 
In the original series, sensitivity and specificity were calculated to be 99 
and 98% respectively. Overall diagnostic accuracy was 99%. Nevertheless, a 
number of other researchers were unable to reproduce the findings. The latter 
reported specificities ranging from 70 to 86% (Peterman and Speicher 1984; 
Hirsch et al 1979; Roth et al 1990). The variable specificity may be attributed to 
protein and lactate dehydrogenase concentration changes in patients with 
congestive heart failure receiving diuretics. In these patients, selective 
elimination of water from the pleural spaces alters the ratio of pleural fluid to 
semm total protein and lactate dehydrogenase ratios (Chakko et al 1989). 
8 
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A number of other investigators then proposed other biochemical criteria for the 
separation oftransudates and exudates. The following measurements have been 
reported to be diagnostic of an exudative pleural effusion: a pleural fluid 
cholesterol level above 1.56 mmol/L (Hamm et al 1987, Valdes et al 1991); a 
serum albumin minus pleural fluid albumin gradient ofbelow 12 g/L (Roth et al 
1990); and a pleural fluid/serum bilirubin ratio above 0.6 (Meisel et al 1990). A 
combination of cholesterol and lactate dehydrogenase levels (cutoff values of 
1.17 mmolfL and 200 IU/L respectively) was said to be most specific and 
sensitive by Costa and coworkers 1995. However, others did not have this 
finding. Differences in methodology and calibration may account for the varying 
results of different studies. 
In addition to the quantitative changes in pleural fluid analytes in diseases 
causing an exudate formation, it is possible that inflammatory changes of the 
pleural capillaries may result in a qualitative alteration in pleural fluid 
constituents. In this study, protein electrophoresis is used to detect such changes. 
Only one paper was found in the literature (Luetscher 1941) which used protein 
electrophoresis to study patterns of protein in pleural fluid in different disease 
states. Yet, no attempt was made in elucidating its role in the differentiation of 
exudate from transudate. It is postulated that low molecular weight molecules 
e.g. albumin (M.W. 66.3 kDa), a l antitrypsin (54 kDa) and transferrin (76.5 
kDa) are able to pass the capillary membrane to enter the pleural spaces in 
transudative pleural effusion while high molecular weight molecules such as a2 
macroglobulin (725 kDa), immunoglobulin (IgA, D, G = 160 kDa; IgE = 190 
kDa; IgM = 950 kDa) and P lipoprotein (250 kDa) will only do so when 
capillary permeability increases in exudative pleural effusion formation. 
2.4 Receiver operating characteristic curve (Zweig and Campbell 1993; 
Henderson 1993; Boyd 1995) 
Receiver operating characteristic curve is a continuous plot of the effect 
of changing the decision threshold on sensitivity and specificity. 
Conventionally, it is a profile of the performance of a diagnostic test in terms of 
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test sensitivity against 1-specificity. Test sensitivity is the true positive rate 
defined as the % positivity of test results in patients who have the disease i.e. 
true positive / (true positive + false negative). Specificity is the true negative 
rate defined as the % negativity oftest results in patients who are free ofdisease 
i.e. true negative / (true negative + false positive rate). In corollary, 1-specificity 
is the false positive rate defined as false positive / (true negative + false positive). 
When the overlap of diseased and non-diseased populations is total, no 
differentiation is possible between the two populations by means of the test 
results. In this situation, the true positive rate (TPR) increases proportionally 
with the false positive rate (FPR) so that the ROC line has a slope of 45°; clearly 
the magnitude of ‘signal + noise, (TPR) and 'noise' (FPR) are equal at all 
analyte cutoff values. As the population overlap diminishes, true positive rate 
increases faster than false positive rate, so that the ROC curve approaches the 
left-hand comer. The point on the curve that is closest to the upper left-hand 
comer of the plot represents the cutoff value or decision limit that provides the 
greatest diagnostic accuracy and represents the efficiency ofthe test. 
Examination of the (geography, of the ROC curve is one way of 
examining the accuracy of the test. To put this empirical parameter into 
quantitative assessment, the area under the ROC curve is calculated which 
denotes the accuracy ofthe test's diagnostic accuracy. The area under the ROC 
curve is in fact equivalent to the non-parametric Mann-Whitney U statistic that 
signifies the probability of correctly ranking a pair of diseased and non-diseased 
patients. An area of0.8, for example, means that a randomly selected individual 
from the diseased group has a laboratory test value larger than for a randomly 
chosen individual from the nondiseased group 80% ofthe time. 
Two slopes of the ROC curve have been derived: the TPR / FPR (or 
sensitivity / 1-specificity) and false negative rate (FNR) / true negative rate 
(TNR) i.e. (1-sensitivity / specificity). The former is the positive likelihood ratio 
while the latter is the negative likelihood ratio. The positive likelihood ratio is 
defined as the probability of obtaining a positive test result in a patient with the 
disease divided by the probability of obtaining a positive test result in a patient 
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without the disease. Likewise, the negative likelihood ratio is defined as the 
probability ofobtaining a negative test result in a patient with the disease divided 
by the probability of obtaining a negative test result in a patient without the 
disease. The likelihood ratio is an expression of probability of test results, given 
the presence (or absence) ofdisease. It is independent of the disease prevalence. 
When applying a test to predict the proportion of positive tests that will 
mean the presence of the target disease, the predictive value is used. Positive 
predictive value (PV+) can be expressed as true positive / (true positive + false 
positive) X 100%. In terms of disease prevalence (^rev), sensitivity (sens) and 
specificity (spec), 
PV+ = (sens)(^rev) / [(sens)(prev) + (100 — spec)(100 - prev)] x 100% 
Negative predictive value (PV-), on the other hand, is the percent probability that 
a negative test result correctly predicts the absence of disease. It is expressed as 
true negative / (true negative + false negative) x 100%. In terms of disease 
prevalence (^rev), sensitivity (sens) and specificity (spec), 
PV- = (spec)(100 一 prev) / [(100 - sens)(j)rev) + (spec)(100 — prev)] x 100% 
The positive and negative predictive values are the values used to predict 
whether a patient has or does not have a disease given the result of a test. The 
value depends on the prevalence of the test population when used in the context 
of a diagnostic test. In a population of low disease prevalence, a positive test 
would mean true disease in only a small number of occasions and vice versa. 
The predictive value of the test can be improved if the prevalence of the test 
population is increased by such means as proper clinical diagnosis and 
performing screening examinations (e.g. radiograph) beforehand. 
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Chapter 3 
Adenosine deaminase (ADA) 
3.1 Background 
Adenosine deaminase (EC 3.5.4.4) is an important enzyme in the 
purine salvage pathway that catalyses the hydrolytic deamination reaction 
of adenosine and deoxyadenosine to yield inosine and deoxyinosine, 
respectively. The reaction involves the release of an ammonium ion. It 
plays a central role in the development of the immune system and is 
essential for immune competence. Figure 1 shows the purine salvage 
pathway. 
ADA has a molecular weight of 217 kDa. It is expressed in all 
mammalian cells, being localized primarily in the cytoplasmic portion of 
many cell types. Elevated semm level is related to T lymphocyte 
differentiation and proliferation and monocyte/macrophage activity or 
turnover (Donma and Donma 1996). The enzyme is released by activated 
lymphocytes and macrophages during the cellular immune response in 
tuberculosis (L'Herminez 1993). Semm ADA level may also be 
increased in scleroderma, infectious mononucleosis, hepatitis, rheumatoid 
arthritis, mycosis fungoides, toxoplasmosis, brucellosis, pneumonia, 
leprosy and acute lymphoblastic leukaemia. 
In addition to tuberculosis, rheumatoid pleuritis and empyema are 
known diseases that cause an elevated pleural fluid ADA level (Light 
1995). 
3.2 Differentiation of tuberculous and non-tuberculous pleural effusion 
The use of adenosine deaminase in the differentiation of 
tuberculous and non-tuberculous pleural effusion dates back to 1978 
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Figure 1. The purine salvage pathway 
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when Piras et al (1978) found a significantly higher ADA level in patients 
with tuberculous pleurisy: mean 士 SD of 83.04 士 25.51 IU/L compared to 
metapneumonic pleurisy (17.26 士 7.51 IU/L) and pleuropulmonary 
malignancy (15.54 土 6.56 IU/L). Later, in a larger study of sample size 
368, Maritz and coworkers (1982) detected similar activity for 
tuberculous pleural effusion. The mean 土 SD ADA activity was 92.11 土 
37.05 IU/L. But ADA samples from patients with para-infective effusion 
were also elevated. The mean 士 SD value was 97.57 土 82 IU/L. It was 
concluded that measurement of ADA level in pleural fluid is 
diagnostically useful because ADA levels tend to be higher in 
tuberculous pleural effusion than in other exudates O^iwa et al 1985; 
Ocana et al 1983; Fontan Bueso et al 1988; Valdes et al 1993). 
Banales and coworkers 1991 carried out a study in which 
significantly higher pleural fluid ADA level were found among TB 
pleuritic patients (mean 士 SD values = 123.25 土 39.4 IU/L). Sensitivity 
and specificity ofthe test were 98% and 96% respectively. Nevertheless, 
no empyematous patients were included in this study. Later, Valdes et al 
1993 carried out a larger study in Spain and reported similar findings of 
higher ADA values. The study population of 405 pleural fluid included 
91 due to tuberculosis, 110 due to malignancy, 58 due to pneumonia, 10 
due to empyema, 88 transudates and 48 miscellaneous. Tuberculous 
pleural fluid has an ADA level of 107.5 士 37.9 IU/L. However, 
empyematous pleural fluid was also found to have elevated ADA level. 
The test sensitivity and specificity were good (Table 2). A smaller study 
by Orphanidou et al 1996 (total sample size = 97, consisting of 33 TB, 33 
malignant effusion and 31 benign non-TB effusion) found that the mean 
土 SD ADA level was 85.6 土 48.9 IU/L among TB patients. But the 
















































































































































































































































































































































































Reports from the Asia are few and Light (1995) queried if the 
lower mean levels of ADA reported were due to ethnic differences or 
methodological differences. 
A Japanese study carried out by Aoki et al 1994 worked out the 
range ofADA level to be 35 to 75 IU/L having a median of 58.6 IU/L in 
their population ofTB patients. The sensitivity (81.8%) and specificity 
(89.3%) were unacceptable. A Singaporean group (Teo and Chio 1987) 
found out the TB pleural fluid ADA level were 88.3 土 25.8 IU/L (range = 
40-145 IU/L). The higher ADA level were associated with better 
sensitivity (96%) and specificity (81%). 
It must be noted that if the patient is immunocompromised and 
has tuberculous pleuritis, the pleural fluid ADA level may be below 40 
IU/L (Hsu et al 1993). Patients with rheumatoid pleuritis frequently have 
ADA levels that exceed 70 IU/L (Valdes et al 1993; Petterson et al 1984) 
as do patients with empyema (Valdes et al 1993; Ocana et al 1988). High 
pleural fluid ADA levels are also found in lymphomas (Ocana et al 
1983), and rarely in nonlymphoma malignancy (Ocana et al 1983, Ferrer 
1997) and intracellular infections (Orriols et al 1992). 
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Chapter 4 
Materials and Methods 
4.1 Patients 
Patients presented with pleural effusion and were receiving 
medical treatment in the Princess Margaret Hospital during 1997 were the 
subjects of this study. 
No selection criteria with respect to the type of disease, age or sex 
were set. Diagnosis was done by a separate group of investigators, 
namely the Chest team physicians of the Princess Margaret Hospital on 
the basis of clinical examinations and laboratory results. 
4.2 Collection and handling of specimens 
Pleural fluid and blood specimens were collected from leftover 
specimens sent to the Chemical Pathology Laboratory for routine total 
protein and lactate dehydrogenase and liver function tests respectively. 
They were collected on the date of receipt. Whenever possible, paired 
samples of fluid and blood collected on the same date were obtained. If 
same-dated specimens were unavailable, blood samples taken within 24 
hours before or after the pleural fluid collection were accepted (Romero 
etall993). 
In collaboration with the Department of Medicine, Princess 
Margaret Hospital, six patient samples ^>aired serum and pleural fluid) 
were collected. The patients were 12-hour fasted. 5 mL each of venous 
blood and pleural fluid were taken at about the same time and were stored 
in plain plastic tubes. This was done with written consent ofthe patients. 
All the blood and pleural fluid were centrifuged and the supernatant 
separated into aliquots and kept in -80°C until analysis. 
As routine investigative procedures, these patients had their 
pleural fluid aspirated for cytology, bacterial culture, mycobacterial 
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culture, white cell count, total protein, albumin, total bilirubin, lactate 
dehydrogenase, total cholesterol and triglyceride measurements. Pleural 
biopsy might be taken ifrelevant pathology was suspected. 
4.3 Diagnostic criteria 
The pleural effusion was individually classified after careful 
evaluation of all clinical and laboratory test results. 
The diagnosis of tuberculous pleuritis required that 
Mycobacterium tuberculosis to be identified by culture or biopsy, or 
caseous granuloma to be present in pleural biopsy specimens. 
Malignant pleural effusion was diagnosed when malignant tissue 
in the pleural cavity was shown by pleural biopsy or cytopathology. 
Effusion was considered parapneumonic when there was an acute 
febile illness associated with pneumonia, lung abscess or bronchiectasis 
in the absence of malignancy and diseases causing transudates and 
pleural fluid bacterial culture was negative. 
Empyema was defined as the presence of purulent pleural fluid 
and positive bacterial culture associated with parapneumonic effusion. 
The category, "other exudates", encompasses effusion that was 
clearly caused by pancreatitis, reactive chest effusion, Dressler's 
syndrome or various other well-documented causes. 
Congestive heart failure was diagnosed when all of the following 
criteria were met: cardiomegaly，radiological evidence of congested 
lungs, peripheral edema and response to treatment for congestive heart 
failure. 
Renal failure was diagnosed when there were raised urea and 
creatinine levels in the presence of clinical evidence of fluid overload and 
an absence ofpurulent sputum, malignancy, or pulmonary infiltrates. 
Nephrotic syndrome was classified when the patient had 
proteinuria, edema and hypoalbuminaemia. Other causes of 
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hypoalbuminaemia were determined when semm albumin level was <30 
g/L in the absence ofproteinuria and histologically proven liver cirrhosis. 
Liver cirrhosis was diagnosed by clinical and laboratory 
evidence of hepatic damage with portal hypertension or 
hypoalbuminaemia. 
4.4 Methods 
4.4.1 Routine chemistries 
Routine chemistries including lactate dehydrogenase, total 
protein, albumin, total bilirubin, total cholesterol, triglyceride were 
performed by Boehringer MarmheimMtachi 747-100 System 
(Boehringer Mannheim, Mannheim, Germany) using BM reagents (for 
total bilirubin, total cholesterol, triglyceride) and Trace® reagents by 
Trace Scientific Ltd., Melbourne, Australia (for lactate dehydrogenase, 
total protein and albumin). 
4.4.2 Protein zone electrophoresis 
Protein zone electrophoresis of pleural fluid and semm were done 
in pairs by using the Beckman Paragon® SPE kit (Beckman Instruments, 
Inc. Fullerton, USA). Pleural fluid was diluted 1 in 3 while serum was 
diluted 1 in 5. The latter dilution was recommended by the manufacturer. 
While no recommendation concerning pleural fluid was given by the 
manufacturer, a trial was carried out to determine the preferred dilution of 
pleural fluid samples. 
4.4.3 Adenosine deaminase 
There are a number of methods for ADA measurement, broadly 
classified into : direct measurement of unreacted radioactively labelled 
adenosine, direct measurement of the rate of decrease in adenosine, 
measurement of inosine formation and measurement of ammonia 
formation. 
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Direct measurement ofunreacted radioactiveIv labelled adenosine 
i4c labelled adenosine is used as substrate. After a definite 
incubation time the reaction is terminated, the substrate, reaction product 
(inosine) and further degradation product (xanthine), are separated by 
chromatography (van der Weyden & Bailey 1978) or by selective 
absorption onto phospho-Sephadex gel (Jackson & Keightley 1975). The 
radioactivity ofunreacted substrate is then counted by liquid scintillation. 
Although this method shows better sensitivity, difficulty to automate 
and the handling ofradioactive materials are the major limitations ofthis 
method. 
Direct measurement ofrate ofdecrease of adenosine 
Decrease in absorbance at 265 nm upon conversion of adenosine 
to inosine is used for ADA measurement (Klenow 1952). However, the 
absorbance of adenosine at 265 nm is high and it is difficult to reach 
saturation conditions. Murphy et al (1982) suggested that when the 
substrate concentration was near 8 x 10"^  M, the deamination reaction 
would proceed with no change in absorbance, due to a negative deviation 
from Beer's law. Nevertheless, Tritsch (1983) disagreed to the 
explanation. While admitting there was lowered ADA activity at high 
substrate concentration, he attributed this phenomenon to substrate 
inhibition instead of deviation from Beer's law. Besides, the method is 
susceptible to turbidity variations during assay. 
Measurement of inosine formation 
In combination with nucleoside phophorylase and xanthine 
oxidase reactions, inosine can be converted to uric acid which shows a 
maximum absorbance at 293 nm (Martinek 1963). 
Adenosine + H2O 隐 > inosine + NH3 
Inosine + P, _nudeosidephosphorylase__�hypoxanthine + ribose-l-P 
Hypoxanthine + ffl2O + 2O2 — x — i n e � x i d a s � ^ f e + 2H2O2 
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However, high concentrations ofprotein, e.g. in semm, which absorbs 
at this wavelength, may interfere. 
Alternatively, the H2O2 formed can be assayed by reacting with 
ethanol to yield acetaldehyde whose formation is coupled to a NAD 
reaction to forai acetate and NADH. Measuring the increase in 
absorbance ofNADH reflects the ADA activity (Heinz et al 1980). 
2H2O2 + 2 e t h a n o l - C a t - e _ �2 acetaldehyde + 4 H2O 
2 acetaldehyde + 2 NAD+ + 2 •―越丫」。d e h y d r o g e n a s e ^ 2 acetate + 2 
NADH + 2 H" 
Yet, this method requires high endogenous levels of nucleoside 
phosphorylase relative to ADA. 
Measurement of ammonia formation 
The appearance of ammonia can be measured by means of 
colorimetric method, ammonia-sensitive electrodes or NADH-dependent 
glutamate dehydrogenase reaction. The Berthelot reaction is a 
colorimetric method in which ammonia forms an intensely blue 
indophenol with sodium hypochlorite and phenol in an alkaline solution. 
Sodium nitroprusside is the catalyst. The ammonia concentration is 
directly proportional to the extinction of the indophenol. The reaction 
catalysed by ADA is stopped at the end of the incubation period by the 
addition ofthe phenol-nitroprusside solution (Karker 1964). 
Colorimetric techniques are subject to interference unless protein 
is precipitated and they do not lend themselves readily to kinetic assay. 
NH3-sensitive electrode requires the use of special equipment. 
Ellis and Goldberg (1970) described a continuous 
spectrophotometric method in which ammonia production is coupled 
through glutamate dehydrogenase to reduced nicotinamide adenine 
dinucleotide oxidation as follows :-
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Adenosine ^八 > inosine + NH4+ 
NADH + N H / + 2 a k e t o g l u t a m t e — G D H _ _ ^ N A D + + L-glutamate 
The resultant fall in absorbance at 340 nm is monitored. 
Measurement at this wavelength permits assay of ADA in materials of 
low specific activity and allows much higher substrate concentrations to 
be employed than direct measurement of rate of decrease of adenosine at 
265 nm. 
Based on the principle of Ellis and Goldberg (1970), Ellis et al 
(1973) and Shibagaki et al (1996), a simple, automated method for 
adenosine deaminase was set up in this project. 
4.4.3.1 Instrumentation 
Cobas Mira Plus analyzer (Hoffman-La Roche Ltd., Basel, 
Switzerland). 
Reagents 
a ketoglutaric acid. K-1750 Lotl6H0386, SigmaChemicalCo. 
P-nicotinamide adenine dinucleotide, reduced form disodium salt. N_ 
8129 Lot 066H78231, Sigma Chemical Co. 
L-glutamic dehydrogenase ( EC 1.4.1.3 ) type II: from bovine liver, 
solution in 50% glycerol, sodium phosphate buffer, pH 7.3, 44 U/mg 
protein, 55 mg protein/mL. G2626 Lot 36 H7175, Sigma Chemical Co. 
Adenosine. A9251 Lot45H0428, Sigma ChemicalCo. 
Adenosine deaminase from calfintestine, solution in glycerol. 234 U/mg 
protein (25°C)，2.0 mg proteinAnL. 102091 Lot 83970420-32, Boehringer 
Mannheim GmbH, Penzberg. 
Adenosine 5'-diphosphate sodium salt from bacterial source. A2754 Lot 
96H7847, Sigma Chemical Co. 
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Trizma® citrate Monobasic 2 Molar solution. T2910 Lot 80H5603, 
Sigma Chemical Co. 
BSA. Fluka, AG. CH-9470, Buchs. 
Lipofundin MCT/LCT 20% emulsion. B-Braun Melsungen AG, 
Germany. 
Bilirubin from bovine gallstones crystalline B-4126, lot 88C-0511, Sigma 
Chemical Co. 
Ammonia solution 25%, Merck 5432. 
Materials 
1. Trizma® citrate buffer, 0.1M 
To 20.4 mL stock trizma® citrate, monobasic 2M solution, add 279.6 
mL deionised water. Adjust pH to 7.35 by careful addition of 25N 
NaOH solution. Measure byapH meter. Store at 4°C. 
2. Reagent mixture 
a ketoglutaric acid 1.1 mM 0.01093 g 
p_NADH 0.29 mM 0.01427 g 
ADP 1 mM 0.02995 g 
Trizma® citrate buffer 0.1 M 50 mL 
Dissolve and store frozen at -80�C. Freshly add 1.24 mL GDH to 
8.76 mL reagent mixture before use. Activity in fmal mixture is 44.1 
U/mL. Do not freeze after addition of GDH. 
3. Start reagent 
Adenosine, 5.3 mM , dissolve 0.09727 g per 10 mL deionised water. 
Add 12N HCL in 10 i^L aliquots to just dissolve the adenosine 
powder. Overaddition ofHCL re-precipitates the adenosine powder. 
Store frozen at -80°C. 
Calculation 
2 
Molar absorptivity ofNADH = 6.22 x 10 
^molar absorptivity ofNADH 二 6.22 x 10'^  
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1 enzyme unit = amount ofADA that converts l^imol ofNADH to NAD+ 
in 1 min in the reaction mixture. 
AA  
activity in IU/L = 
6.22 X 10_3 X pathlength x sample volume/total volume 
when sample volume and total volume are in litres. 
Since pathlength = 0.6 cm, sample volume = 15 x 10'^  L, total volume 二 
340 X 10_6 L, activity = 6073.60 x AA 
The measurement parameters of adenosine deaminase in Cobas 
Mira Plus analyzer are listed in table 3. 
4.4.3.2 Optimization of reaction time 
Essentially the method by Shibagaki et al (1995) was used. Two 
optimal reaction time were compared by running the assay at three levels 
ofADA spiked transudate (Lo，Mid, Hi). Reaction times of 10 minutes ( 
cycle 40) and 14 minutes (cycle 50) were compared to obtain optimal 
reaction. 
4.4.4 Analytical performance 
4.4.4.1 Imprecision 
Three ADA levels of pleural fluid were studied. Using Light's 
criteria ( Light et al 1972 ), transudative pleural fluid was selected and 
pooled to constitute the low (L) level material. Medium (M) and high 
(H) level materials were prepared by spiking the low (L) level material 
with commercial ADA solution ( Boehringer Mannheim, GmbH, 
Penzberg ). 
(i) M 12 i^L of stock commercial ADA was added to 
3732 i^L of pooled transudate to make up a 
solution ofapproximately 1500 IU/L of ADA. The 
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Table 3. Parameter listing for measurement of adenosine deaminase 
using Cobas Mira Plus analyzer (Roche) 
MEASUREMENT MODE ABSORB 
REACTION MODE R-S-SR1 
CALIBRATION MODE FACTOR 
REAGENT BLANK REAG/DIL 
WAVELENGTH 340 nm 
UNIT IU/L 
SAMPLE VOLUME ( i^L) 15 
DILUENT VOLUME ( i^L) 25 
REAGENT VOLUME ( i^L) 250 
START R1 VOLUME ( i^L) 50 
SAMPLE CYCLE 1 
REAGENT CYCLE 1 
START R1 CYCLE 15 
REACTION DIRECTION DECREASE 
CALCULATION STEP A IONETIC 
TIME OF FIRST READD^G (sec) 400 
TIME OF LAST READESfG (sec) 1000 
FACTOR 6073.60 
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solution was diluted 1 in 20 with pooled transudate 
to give a nominal concentration 75 IU/L ADA. 
(ii) H The concentrated ADA preparation of 
approximately 1500 IU/L mentioned above was 
diluted 1 in 10 to give a solution having 
approximately 150 IU/L of ADA. 
20 samples of each of L, M and H were assayed in a single run for 
within-run imprecision. Between-run imprecision was assessed by 
nmning the three levels in duplicate every other day for 10 times. 
4.4.4.2 Recovery 
Accuracy was assessed by recovery study. The procedure 
involves adding different amounts ofADA solution (1500 IU/L) or saline 
to pooled transudative pleural fluid as in Table 4 and each sample was 
run in duplicate. 
4.4.4.3 Lowest detection limit 
20 aliquots of0.1 % bovine serum albumin ( Fluka AG, CH-9470, 
Buchs ) were assayed for ADA in a single run. The data are computed 
for the mean and SD. The mean + 3SD value was taken as the lowest 
detection limit. 
4.4.4.4 Linearity 
A 0.1% BSA (Fluka AG, CH-9470, Buchs) was prepared in 
saline. A 3000 IU/L ADA solution was then prepared by adding 15 i^L 
commercial ADA preparation to 3732 i^L 0.1% BSA. Different levels of 
spiked ADA solution were prepared according to Table 5. Each level of 
solution was assayed in duplicate. 
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Table 4. Preparation ofpleural fluid for recovery study 
— I ~ ~ ~ ~ 2 " ~ " " " 3 ~ ~ ~ ~ 4 ~ ~ ~ ~ 5 6 1 g 
Transudate 9 9 0 " " " ^ ^ ~ ~ ^ " " ^ ^ " " ^ ^ " ~ ~ ^ " " ^ " " " ^ 
OtL)  
Saline(nL)"""l0 ^ ^ - ^^ … • “ “ 
i500nj/L ：：：： Io ^ 40 ^ ^ - 蘭 
ADA — TTT— 
Estima;d 15 0 60 0 75 0 150 
ADA spiked 
(RJ/L)  
Table 5. Preparation ofpleural fluid for linearity study 
1 2 3 4 5 6 7 8 9 10 H 12— 
- ^ " " " ^ I ^ " ^ " W " ^ " 5 5 T ^ ^ " ^ " ^ " ^ " ^ ^ ^ 780 
3^000iS 0 " ~ 2 ^ — ^ ^ ^ ^ ^ ^ ^ ^ " ^ 
A D p = L ) _ _ - ~ ~ 而 " “ ^ r ^ " T i r - ^ ^ ^ " ^ ^ ^ " ^ " ^ ^ ^ " ^ 
ADA conc 




4.4.4.5 Interference by ammonia 
Concentrated ammonia solution of approximately 13.7 mol/L was 
diluted 1 in 3425, i.e. 5 i^L added to 17.12 mL deionised water to make 
up a 4000 ^imol/L stock ammonia solution. The stock is then serially 
diluted with deionised water till 1 in 128. A pooled transudate was 
prepared and then spiked with commercial ADA (Boehringer Mannheim, 
GmbH, Penzberg) to a final concentration of approximately 90 IU/L. 70 
I^ L each of diluted ammonia solution was then added to 280 i^L of 90 
IU/L ADA preparation. 70 ^L of deionised water was added instead of 
diluted ammonia solution as a control. Ammonia concentration and 
ADA activity were measured in duplicate. 
4.4.4.6 Interference by turbidity 
Lipofundin emulsion was serially diluted with normal saline down 
to a dilution of 1 in 128. A spiked pooled transudate of approximately 90 
IU/L ADA was prepared as follows : 
Add 12 i^L of commercial ADA stock solution ( Boerhinger Mannheim, 
GmbH, Penzberg ) to 1236 ^L pooled transudate to constitute a 9000 
IU/L ADA preparation. 30 i^L ofthe preparation was then added to 2970 
^L of pooled transudate. The 1 in 100 dilution constitutes a 90 IU/L 
ADA preparation. 
70 i^L ofneat or diluted Lipoflmdin each was added to 280 i^L of 
spiked pooled transudate ( ADA activity of 90 IU/L ). Normal saline was 
added in place ofLipofundin as a control. ADA activity and triglyceride 
concentrations were measured in duplicates. 
4.4.4.7 Interference by haemoglobin 
Red blood cells were pooled from lithium heparin anticoagulated 
blood and washed with normal saline for 6 times. The washed red cells 
were frozen at -80 degrees Celsius overnight and thawed at room 
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temperature to lyse the red cells. Haemoglobin concentration of the 
haemolysate was measured by Sysmex Cell counter ( Toa Medical 
Electronics, Kobe, Japan ) to be 28.2 g/dL. The haemolysate was then 
diluted 1 in 2 using normal saline. Using normal saline, serial dilutions 
of the diluted haemolysate were made down to a haemoglobin 
concentration of about 0.2 g/dL. On the other hand, a spiked ADA 
solution of 90IU/L activity was prepared with pooled transudate. 100 i^L 
of haemolysate of different haemoglobin concentrations was added to 
400 iiL of90 IU/L spiked pleural fluid. Normal saline was added instead 
of haemolysate as a control. ADA activity and haemoglobin 
concentration was assayed in duplicate. 
4.4.4.8 Interference by bilirubin 
A bilirubin solution was prepared by dissolving 0.01754 g of 
bilirubin powder (from bovine gallstones crystalline B-4126, lot 88C-
0511, Sigma Grade, Sigma Chemical Co.) in 10 mL deionised water. 
The bilirubin solution was diluted 1 in 10 and its bilirubin concentration 
determined by Synchron CX5 analyzer (Beckman Instruments, Inc. 
Fullerton，USA.) to be 270 ^imol/L. Various dilutions of this solution 
were made as tabulated in Table 6. 
70 ^L of different bilirubin solution was added to 280 [iL of 
spiked pooled transudate of ADA activity 90 IU/L. Deionised water was 
added instead as a control. ADA activity and bilirubin concentration 
were measured in duplicate. 
4.4.4.9 Storage stability ofADA at -80°C 
The stability ofADA was verified by performing the QC samples 
(L, M, H as described) over a period of6 months. 
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4.4.5 Statistical Analysis 
Data were expressed as mean 士 SD and median (range). 
Distribution was assessed by plotting histogram and calculating skewness 
and kurtosis. The statistical significance of the means between the 
populations were calculated by Student's t test if the populations were 
Gaussian. Otherwise, Mann Whitney U test was used. Logistic 
regression analysis was used to examine the best combination oftests for 
classification of TB and non-TB exudates. Cutoff values were 
established by using the receiver operating characteristic curve. The 
prevalence of tuberculosis of the test population was calculated by 
dividing the number of tuberculous effusion by the total number of 
effusion. 
Table 6. Preparation of pleural fluid for bilirubin interference 
study. 
Deionised ~ " 0 ~ " 60 130 200 260 330 365 386 
water (p>L)  





RESULTS OF OPTIMIZATION AND EVALUATION EXPERIMENTS 
5.1 Optimization results 
The ADA activities calculated by multiplying the absorbance 
change with the factor for the three levels of pooled pleural fluid were 
listed in Table 7. 
There was no significant differences between 10 and 14.1 
minutes. A shorter reaction time of 10 minutes was chosen so as to 
shorten the assay time. 
5.2 Analytical performance 
5.2.1 Imprecision 
5.2.1.1 Within-run 
The within-run imprecision of the ADA assay estimated using 
pooled and spiked transudative pleural fluid samples L, M, H were 
5.32%, 0.82% and 0.50% respectively while that of cholesterol assay 
using precipath (Boehringer Mannheim, GmbH, Penzberg) was 1.56% 
(Table 8). 
5.2.1.2 Between-run 
Between-run imprecision of the ADA assay estimated using 
pooled and spiked, pooled transudative pleural fluid samples L, M and H 
were 9.82%, 1.50% and 1.26% respectively while that of cholesterol 
assay using precipath (Boehringer Mannheim, GmbH, Penzberg) was 
2.22% (Table 9). 
5.2.2 Recovery 
Results of recovery study was shown in Table 10. The % recovery varied 
from 99.9 to 109.1% for the enzyme concentrations spiked. 
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Table 7. Comparison of effect of reaction time on ADA activity 
Calculated ADA activity (KJyT.) 
reaction time 10 min 14.1 min 
L ^ 1 ^ r o ^ 
Medium 7 4 ^ 7 ^ 
H^h 136.53 137.40 
Table 8. Within-mn imprecision of ADA and cholesterol assays 
Control ~~Analytes~~~ N Mean §5 %CV 
sample  
L ADA ^ 9.58 0.51 5.32 
M ADA ^ 75.80 ^ ^ 
H ADA W 150.53 ^ ^ 
~~Precipath cholesterol ^ L4l 0.022 1.56 
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Table 9. Between-run imprecision of ADA and cholesterol assays 
~Control""^ Analytes N ~ ~ M e a n " ^ SD %CV 
sample  
L A D A " ^ 29 11.10 1.09 9.82 
M ADA ^ ^ ^ 4 L ^ " " " 
H ADA n 150.24 ^ 9 ^26"~~ 
precipath~"cholesterol 20 0 5 0.0308•"“ 2.22 
Table 10. Recovery study of ADA assay 
ADA spiked ( JUfL) ADA activity recovered % recovery 
(RJfL) 
15 1 ^ 1 ^ 
^ 5^1 ^ 
Ts ^ i ^ 
m 150.85 5 ^ 
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5.2.3 Lowest detection limit 
The ADA activity for the twenty 0.1% BSA samples assayed ranged 
from <1.0 to 2.47 IU/L. The mean value was 1.31 while the one SD value 
was 0.4346. Hence the lowest detection limit, defined as +3SD of the mean 
value is 2.62 IU/L. 
5.2.4 Linearity 
The linearity curve of the ADA assay was shown in Fig. 2 and the 
mean measured ADA activity was tabulated in Table 11. 
The linearity was found to be up to 200 IU/L, beyond which the 
curve started to flatten and then declined probably due to substrate 
depletion. This value represents the upper analytical range ofthis assay. 
5.2.5 Interference by 
5.2.5.1 Ammonia 
The effect of ammonia on ADA activity was shown in Table 12. Within 
the range of ammonia tested, the effect was found to be minimal. The 
consumption of substrate by endogenous ammonia does not seriously affect 
measurement of ADA because only a 4% decrease in ADA level was 
observed at an ammonia concentration of 525.5 ^imol/L. Nevertheless, 
condition that would severely increase ammonia concentration should be 
avoided. This includes prolonged storage of specimens unseparated from 
the red cells and platelets which may release ammonia into the plasma or 
fluid. ADA enzymes purchased should not contain ammonia (as 
anunonium sulphate) as preservative. 
5.2.5.2 Turbidity 
Table 13 tabulated the effect of turbidity on measured ADA activity. It 
can be seen that triglyceride level of up to 23.45 mmolyT. had little effect 
on ADA activity. At triglyceride levels of 88.8 and 193 mmoL^, +14 and 
+21% increase in ADA were observed. 
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Figure 2. Linearity plot of ADA assay 
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Table 11. Linearity of ADA assay 
% oforiginal activity mean measured ADA expectedADAactivity 
activity (RJ/L) (狐） 
0 0 0  
2 60.39 一 60  
4 120.25 一 l_20  
6 180.43 ~ " l_^  
8 230.00 ^  
10 — 283.81 300 
12 323.78 360 
14 — 358.84 420 
16 379.44 180  
18 397.80 5 ^  
20 404.27 ^  
22 405.26 660 一 
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Table 12. Effect of ammonia on ADA assay 
Ammonia ADA activity ~~% of original~ 
concentration (DJ/L) 
( i^moVL)  
<12.0 78.07 100 
68.0 75.85 97.2 
75.0 76.09 97.5 
129.5 77.30 99.0 
134.0 77.15 98.8 
147.5 76.09 97.5 
175.5 76.40 97.9 
213.5 77.53 99.3 
281.5 77.82 99.7 
407.0 74.98 96.0 
525.5 75.09 96.2 
Table 13. Effect of turbidity on ADA assay 
Measured ADA activity % of original 
triglyceride (KJ/L) 
concentration 
(mmolyT )^  
0 ^ 77.06 100 
1.86 79.06 103 
2.75 78.16 101 
4.28 78.48 102 
7.87 78.59 102 
23.45 78.10 101 
88.75 87.72 114 
192.9 92.97 121 
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5.2.5.3 Haemoglobin 
Haemolysis showed a marked effect on the ADA assay (Table 14). 
There was a 9% positive bias of ADA activity at a haemoglobin 
concentration of0.1 g/dL. At haemoglobin of 0.3 g/dL, +10% increase in 
ADA was observed. Higher concentrations of haemoglobin further 
increases the apparent ADA level, reaching +139% at a haemoglobin 
concentration of2.3 g/dL. 
5.2.5.4 Bilirubin 
The effect of bilirubin on the ADA assay was smaller than 4% for all 
levels ofbilimbin tested. (Table 15) 
5.2.6 Storage stability of ADA at -80°C 
During the entire period experiments of roughly 6 months, the measured 
ADA activity of frozen controls was quite constant. For example, the 
coefficient of variation of controls L, M and H were 9.59% [n 二 29，mean 
(SD) = 11.05 (1.06)], 2.06% [n= 32，mean (SD) = 75.86 (1.56)] and 3.64% 
[n= 31, mean (SD) = 146.80 (5.35)]. It showed that ADA activity was 
stable for at least 6 months if the sample was stored at -80°C. 
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Table 14. Effect ofhaemolysis on the ADA assay 
~ " H b ( g/dL ) ~ ~ Activity (IU/L ) % of original  
ADA 
0 ^ i ^ 
o l 7 ^ ^ 
03 7 ^ no 
06 ^ ^ n 3 
u 8 ^ m 
^ 9 ^ 1 ^ 
Table 15. Effect of bilirubin on the ADA assay 
~"Bilirubin conc.~~ ADA activity (IU/L) % of original ADA 
(umol/L)  
5 7 ^ 100 
^ 72M 5 ^ 
^ 7LU ^ 
% 7 L ^ ^ 
1 ^ 6 ^ % 
^ nM ^ 
^ m 5 ^oI 
m 72.55 5 ^ 
^ 7 L ^ ^ 
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Chapter 6 
TRANSUDATIVE AND EXUDATIVE PLEURAL EFFUSION 
6.1 Results of routine chemistries 
72 patients studied have diagnoses that fit the diagnostic criteria set out in 
section 4.3. The causes of effusion are shown in table 16. Table 17 and 18 
summarize the distribution ofthe results for transudates and exudates. With the 
exception oftriglyceride and its pleural fluid to semm ratio, all analytes and their 
pleural fluid to serum ratios have statistically significant difference between the 
transudative and exudative patient groups. The results are also shown 
graphically in figures 3 to 14. 
6.2 Decision thresholds by ROC curve 
Using ROC curve analysis for pleural fluid total protein, albumin, total 
bilirubin, lactate dehydrogenase, total cholesterol and the respective pleural fluid 
to semm ratios ofthe analytes, the optimal cutoff values were determined (Table 
19). The areas under the ROC curve were tabulated in table 20. 
6.3 Discussion 
Among the chemistries analysed, total protein, albumin and lactate 
dehydrogenase had the largest areas under the ROC curve, being 0.821, 0.809 
and 0.805 respectively (standard errors = 0.0614, 0.0613 and 0.0816 
respectively). The areas under the ROC curve for the five pleural fluid to semm 
ratios were about the same. 
It was found that the optimal cutoff values for total protein ratio and 
lactate dehydrogenase ratio were 0.55 and the optimal cutoff value for pleural 
fluid lactate dehydrogenase level was 200 U/L. Using a combination of these 
three parameters, the sensitivity for exudate identification could be improved to 
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Table 16. Causes of studied pleural effusion 





Parapneumonic disease 4 
Pneumonia 4 
Other exudates 
Reactive effusion to chest infection 1 
Reactive effusion to subphrenic abscess 1 
Acute cholangitis 1 
Acute pancreatitis 1 
Transudate 21 
Congestive heart failure 9 
Cirrhosis ^ 
Hypoalbuminaemia 3 
End stage renal failure 3 
Connective tissue disease 2 
Nephrotic syndrome 1 





































































































































































































































































































































































































































































































































































































































































































































Figure 11. Scatterplot ofpleural fluid to serumtotal bilirubin ratio 
(Dotted line represents the mean of the population) 
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Figure 4. Scatterplot of pleural fluid albumin 
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Figure 11. Scatterplot ofpleural fluid to serumtotal bilirubin ratio 
(Dotted line represents the mean of the population) 
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Figure 6. Scatterplot ofpleural fluid lactate dehydrogenase 
(Dotted line represents the mean of the population) 
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Figure 11. Scatterplot ofpleural fluid to serumtotal bilirubin ratio 
(Dotted line represents the mean of the population) 
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Figure 8. Scatterplot of pleural fluid triglyceride 
(Dotted line represents the mean of the population) 
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Figure 9. Scatterplot ofpleural fluid to semm total protein ratio 
(Dotted line represents the mean of the population) 
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Figure 10. Scatterplot of pleural fluid to serum albumin ratio 
(Dotted line represents the mean of the population) 
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Figure 11. Scatterplot ofpleural fluid to serum total bilirubin ratio 
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Figure 12. Scatterplot ofpleural fluid to serum lactate dehydrogenase ratio 
(Dotted line represents the mean of the population) 
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Figure 13. Scatterplot ofpleural fluid to serum total cholesterol ratio 
(Dotted line represents the mean of the population) 
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Figure 14. Scatterplot of pleural fluid to serum triglyceride ratio 
(Dotted line represents the mean of the population) 
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Table 19. Optimal cutoffvalue for five pleural fluid analytes and their 
respective pleural fluid to semm ratios 
~" Sensitivity (%) Specificity (%) Sum Cutoff 
Pleural fluid 
TP 67 76 143 36 g/L 
^ ^ E m 20g/L 
"5H 43 ^ m 8 ^imol/L 
^ D ^ ^ 1 ^ 200 U/L 
^ ^ 76 13¾ 1.2mmol/L 
TP ratio T e ^ H9 Q-^ ^ — 
Alb ratio ^ ^ H3 0.58 
Bil ratio ^ ^ 5 ^ 0.61 — 
LD ratio T% ^ 151 0.55 
Chratio ^ ^ ^ ^ ^   
1  
Table 20. Areas under the ROC curves for the analytes 
Pleural fluid Pleural fluid to serum ratio 
AUC S l AUC SE 
TP 0 ^ 0.0614 0 ? m 0.0758 
Alb 0 ^ 0.0613 0 ? ^ 0.0729 
BU 0 ^ 0.0840 0.722 0.0819 
LD 0 ^ 0 M 6 07m 0.0829 
a o?m 0.0622 o?m 0.0702 
AUC = area under the ROC curve 
SE = standard error of area under the ROC curve 
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92.7% and the specificity is 53.3%. The Light's criteria need modification when 
applied to the local population. 
Other criteria as introduced in section 2.3 were used, the criterion by 
Hanrni et al 1987 and Valdes et al 1991 (total cholesterol >1.56 mmol/L) yielded 
a low sensitivity (51.2%). A cutoffusing total bilirubin ratio >0.6 alone (Meisel 
et al 1990) gave a sensitivity of 87.8% but specificity was unacceptably low 
(26.7%). The criteria by Costa et al (1995) using a pleural fluid cholesterol value 
of>1.17 mmol/L and a pleural fluid lactate dehydrogenase level of >200 U/L 
was the best. Fulfillment of any one of these two criteria was considered 
diagnostic for an exudative pleural effusion. A 92.7% sensitivity and 73.3% 
specificity was obtained. 
The cutoffvalues used were almost identical to our findings for these two 
parameters. Using the optimal cutoff values that were obtained in this study ( 
pleural fluid total cholesterol of >1.2 mmol/L and pleural fluid lactate 
dehydrogenase activity of >200 U/L, the same sensitivity and specificity were 
obtained. Since the prevalence of exudative pleural effusion was 73.2%, the 
positive predictive value was 90.5% and the negative predictive value was 
78.6%. It is concluded that the criteria by Costa et al 1995 is the best 
combination oftests for the discrimination of exudate and transudate. 
6.4 Results of protein zone electrophoresis 
115 paired samples of pleural fluid and semm were analyzed by protein 
zone electrophoresis. However, only 53 cases had confirmed diagnoses. Among 
them, 41 were exudates while 12 were transudates. Table 21 shows the 
composition of their diagnoses. 
Using the interpretative criteria listed in section 4.3，38 exudates (92.7%) 
were correctly diagnosed (38/41) while 4 transudates (33.3%) were correctly 
diagnosed (4/12). 
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Table 21. Etiology of pleural effusion for protein zone electrophoresis 





Parapneumonic disease ^ 
Pneumonia ^ 
Reactive effusion to chest infection 1 
Reactive effusion to subphrenic abscess 1 
Cholangitis 1 
Transudate 12 
Congestive heart failure 1 
Cirrhosis 1 
Hypoalbuminaemia 4 
End stage renal failure 3 
Connective tissue disease 1 
Nephrotic syndrome 1 
Acute pulmonary edema 1 
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In figure 15，electrophoretograms oftransudates are shown. Only small 
molecular weight molecules such as albumin, a l antitrypsin and transferrin were 
observed in pleural fluid samples and no high molecular weight molecules were 
present. 
Typical electrophoretic patterns of exudative pleural effusion are shown 
in figure 16. When noticeable a2, lipoprotein and y bands are present, the fluid 
is referred to as an exudate. 
In 2 of the proven exudates that were wrongly classified as transudate 
based on the diagnostic criteria listed in section 4.3, a diffuse a2 band was 
present (figure 17, lanes 1, 3). In the remaining case diagnosed clinically as 
having parapneumonic disease, the protein electrophoresis was clear (figure 17, 
lane 5). The patient is a 95 year old female with no history of use of diuretic but 
she has hypoalbuminaemia (serum albumin = 25 g/L). 
In 2 proven transudates that were falsely classified as exudates, the 
albumin band was darker in colour but no other bands were present (figure 18, 
lanes 1 and 3). The remaining 6 falsely classified samples all had electrophoretic 
characteristics ofexudates (figure 18, lanes 5, 7, 9，11，13, 15). 
6.5 Discussion 
The sensitivity of detecting exudative pleural effusion can be increased 
by adding an interpretative criterion that when a diffuse a2 band is present, the 
fluid is classified as an exudate. By doing so, 40 exudates (97.6%) will be 
classified correctly (40/41). Besides, when albumin and a 丫 band is present 
without other high molecular weight bands, the fluid is designated an exudate. 
In order to reduce false classification of transudates as exudates, the 
presence of intense albumin band should not be regarded as diagnostic for 
exudate. Instead, the protein electrophoresis should be repeated with the pleural 
fluid at the same dilution as that ofthe serum sample (i.e. 1 in 5). Ifthe band in 
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Figure 15 Typical patterns ofelectrophoresis oftransiidates 
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Figure 16 Typical patterns of electrophoresis of exudates 
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Lanes 1，3，5，7，9，11 are pleural fluid. 
Lanes 2，4，6，8，10，12 are sera, 
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Figure 17. Proven exudates classified as transudates. 
Lanes 1，3，5 are pleural fluid. 
Lanes 2，4，6 are sera. 
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Figure 18. Proven transudates classified as exudates 
Lanes 1，3, 5，7，9，11,13，15 are pleural fluid. 
Lanes 2，4，6，8,10，12，14，16 are sera. 
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the former sample is not more intense than the albumin band of the latter, the 
pleural fluid should be classified as a transudate. 
6.6 Comparison of protein zone electrophoresis and Light's criteria 
The performance of the protein zone electrophoresis and the Light's 
criteria in the differentiation of exudate and transudate was compared. As 
tabulated in table 22, there are a total of 38 exudates and 8 transudates. The 
Light's criteria classified 36 exudates (94.7%) and 2 transudates (25%) correctly 
while protein zone electrophoresis classified 37 exudates (97.4%) and 1 
transudate (12.5%) correctly. 
6.7 Discussion 
The protein zone electrophoresis is as sensitive as, if not better than, the 
Light's criteria in identifying exudates. The Light's criteria failed to identify an 
exudate due to pneumonia (figure 19, lane 1). The protein zone 
electrophoretogram clearly shows an a2 band and a y band. However, in one 
case diagnosed to be parapneumonia, apparently the protein zone electrophoresis 
has a pattern of a transudative effusion (figure 19, lane 3). In addition, the 
patient has a low fluid protein level (total protein = 24 g/L), the total protein ratio 
二 0.38, fluid LD level = 79 U/L and LD ratio = 0.31. The clinical diagnosis is 
doubted and the patient deceased, so a complete diagnostic workup was not 
possible. 
On the other hand, the performance of the Light's criteria and the protein 
zone electrophoresis in transudate identification were similar. In a case of 
nephrotic syndrome, the Light's criteria classified it as a transudate (total protein 
ratio 二 0.33, LD ratio 二 0.18 and fluid LD = 47 U/L) but the protein zone 
electrophoresis classified it as an exudate because an a2 band and a y band were 
present (figure 19, lane 5). On further examination, the patient also suffered 
from systemic lupus erythematosus which probably complicated the influence of 
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Table 22. Number of correctly diagnosed exudates and transudates. 
Total no. of Light's criteria (% correct) Protein zone electrophoresis 
exudates (% correct) 
3S 36 (94.7%) 37 (97.4%) 
Total no. of~~ Light's criteria (% correct) Protein zone electrophoresis 
transudates (% correct) 
8 2 (25%) 1 (12.5%) 
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Figure 19. Electrophoretograms of discrepant results from 
etiological diagnosis 
Lanes 1，3，5,7，9，11，13，15，17 are pleural fluid. 
Lanes 2，4，6，8，10，12，14，16，18 are sera. 
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nephrotic syndrome in pleural fluid formation. It is suspected that this patient 
has a dual pathology in pleural effusion formation. 
There is one case of transudate due to hypoalbuminaemia missed by both 
the Light's criteria and the protein zone electrophoresis. The fluid LD level is 
high (= 41732 U/L) and there is a y band in the electrophoretogram (figure 19, 
lane 17). There may possibly be other underlying pathological mechanism in 
this case. 
In the remaining 5 cases of transudates classified wrongly by both 
methods, the patients suffered from hypoalbuminaemia and congestive heart 
failure (1)，end stage renal failure (2), connective tissue disease (1), and acute 
pulmonary edema (1) (figure 19，lanes 7, 9, 11, 13，15) 
In summary, there is a good agreement between the results obtained by 
the protein zone electrophoresis and the established Light's criteria. It is found 
that while the Light's criteria provides quantitative information about a pleural 
fluid's nature, protein zone electrophoresis provides additional qualitative 
information for the differentiation of exudate from transudate. Moreover, the 
simple technique revealed subtle changes that occur in the pleural capillaries 
\ resulting in an increased protein permeability. These changes will not be 
visualized by other quantitative analytical measures. 
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Chapter 7 
Tuberculous and non-tuberculous exudative pleural effusion 
7.1 Results of adenosine deaminase assay 
The causes of pleural effusion and the number of patients in each 
diagnostic group shown in parentheses are as follows: tuberculosis (15), 
malignancy (41), empyema (6). The mean ADA levels and their distribution in 
tuberculous and non-tuberculous exudative pleural effusion are listed in Table 
23. 
There was significant difference between the means of pleural fluid ADA 
level (p<0.0001) and pleural fluid / serum ADA ratio (p= 0.0023) of the two 
groups. However, there was no significant difference between the groups in 
terms of semm ADA levels Op= 0.1007). 
All the tuberculous effusion had pleural fluid ADA levels of 46 IU/L or 
more, whereas 95% of patients with neoplastic disease (36/38) and 50% of 
empyema cases (3/6) had pleural fluid ADA values below this level. The 
scatterplots shows the distribution of the data (figures 20, 21, 22) 
7.2 Combinations of analysis 
When the six analytes (total protein, albumin, total bilirubin, lactate 
dehydrogenase, total cholesterol and triglyceride) were put into the logistic 
regression model in addition to pleural fluid ADA, all of them were shown to be 
statistically insignificant (Table 24). There were also no statistical significance 
of each of the ratios when the pleural fluid to semm ratios of the six analytes 
were incorporated, in addition to pleural fluid ADA level, into the logistic 
regression model (Table 25). 
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Table 23. ADA levels in TB and non-TB exudative pleural fluid 
f N Pleural fluid ADA level Serum ADA level Pleural fluid 
(IU/L) (IU/L) /semm ADA 
ratio  
"TBeffusion"""lS~~~"81.88±22.42 "39.85 ±32.11 2 . 5 3 ^ ^ ' 
76.16(46.01- 124.71) 31.02 (17.78- 2.58 (0.97-
126.15) 3.76) 
^ ? f B ^ 28.91i20.93 28.90士23.65 !.^！士？/ 
Exudative 22.53 (5.99- 113.6) 20.02 (12.93- 1-0 (O.H-
effusion 131.4) . _ 1 : ^  
" ^ S ^ ^ ^ ^ ^ ; j ; ^ " ^ s ^ j ^ ^ 5 t ; ; ; ^ ^ ^ ; ; J ; ^ ; 5 ^ ^ ^ 
Data are expressed as mean 土 SD and median with range in parenthesis. 
*Mann-Whitney U test 
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Figure 20. Scatterplot of pleural fluid ADA levels in TB and 
non-TB patients 
(Dotted line represents the mean of the population) 
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Figure 21 . Scatterplot of semm ADA levels in TB and non-TB patients 
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Figure 22. Scatterplot of pleural fluid to semm ratio in 
TB and non-TB patients 
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Table 24. Logistic regression analysis of pleural fluid ADA level and 6 
routine chemistries 
Total albumin bilirubin~~LD cholesterol~~triglyceride 
protein 
^ 0 ^ 0.9589 0.2721 0.2306~~0.1467 0.9017 
value 
Table 25. Logistic regression analysis of pleural fluid ADA level and 
ratios ofpleural fluid to serum levels of 6 routine chemistries. 
— Ratio 
Total albumin bilirubin LD Cholesterol triglyceride 
protein 
~ ~ ^ 0 7 I ^ 0 3 ^ 0.2041 0.6110 0.6662 0.2390~~ 
value 
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7.3 Decision thresholds by ROC curve 
The ROC plot of tuberculous vs non-tuberculous exudate pleural fluid 
ADA is shown in figure 23. 
The area under curve was 0.9574 (standard error = 0.0247; 95% 
confidence interval = 0.909 to 1.000). At a cutoff value of 53 IU/L, the 
sensitivity and specificity are 93.3% and 89.36 respectively. The prevalence of 
tuberculous pleurisy in the test population is 24.19%. Hence, the positive and 
negative predictive values are 73.68% and 97.67% respectively. The efficiency 
of the test is 90.32%. At this cutoff value there is only 1 false negative and 5 
false positives. 3 out ofthe 5 false positives are due to empyema. When a cutoff 
of 45.81 IU/L is used, the test is 100% sensitive. On the other hand, when a 
cutoffofll3.6 IU/L is used, the specificity raises to 100% (Table 26). 
7.4 Discussion 
Our pleural fluid ADA result has a mean and SD and range lower than 
those reported in the European and South African studies [Burgess et al 1996, 
median= 103, 25'^  percentile= 75, 75也 percentile= 141); Valdes et al 1996 (mean 
土 SD 二 127.5 土 32.9 IU/L); Banales et al 1991 (123.25 士 39.4 IU/L); Valdes et al 
1993 (107.5 土 37.9 IU/L)]. Yet, the findings of this study are higher than those 
by the Japanese group Aoki et al 1994 (median = 58.6, range 二 35-75 IU/L) and 
are similar to those obtained by the Greece group Orphanidou et al 1996 (mean 土 
SD 二 85.6 士 48.9 IU/L) and the Singaporean group [Teo and Chio 1987 (mean 土 
SD = 88.3 土 25.8 IU/L), range = 40-145 IU/L). 
The lower values obtained in our study may be due to ethnic variations 
between westem and Chinese populations or due to methodological differences. 
\ 
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Figure 23 ROC plot of TB and non-TB pleural fluid ADA levels 
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Table 26. Sensitivities and specificities of ADA assay at different cutoff 
values. 
Pleural fluid ADA Sensitivity Specificity Sum 
cutoff(IU/L) 
4 m m ^ ^ 
53 93.33 89.36 182 
113.6 13 100 113 
Table 27. Relationship of sum of sensitivity and specificity to overall 









<100 Less than useless 
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All ofthe quoted study except the one by Aoki et al 1994 used Giusti 
method (Giusti 1974). Aoki et al used a NADH-linked method which is 
probably the same as ours. Light 1995 suggested that the lower ADA level 
among Asians may compromise its usefulness in TB detection in these 
populations. Nevertheless, using a cutoff value of 53 IU/L, we obtained 93% 
sensitivity and 89% specificity. These values are better than some ofthe western 
studies (Burgess et al 1996; Orphanidou et al 1996). Our results are also better 
in terms of sensitivity and specificity than those obtained from another Asian 
group [Aoki et al 1994, (sensitivity = 81.8% and specificity = 89.3%)]. 
The low prevalence (24%) in our test population causes the positive 
predictive value to be only 74% but the negative predictive value is high (98%). 
Hence a low value below the cutoffthreshold is very likey to mean the absence 
of TB in our hospital population setting. 
To further enhance the ability to differentiate TB from non-TB exudates, 
a multiple cutoffapproach as proposed by Pierce and Cornell (1993) can be used. 
An ADA level > 81 IU/L is 100% specific for TB provided that empyema has 
been excluded. Meanwhile, an ADA level above 46 IU/L is 100% sensitive. 
Results below this level rules out TB as the cause of exudative pleural effusion 
unless the patient is leucocytopenic or immunocompromised. 
The sum of sensitivity and specificity at each decision threshold 
represents how close the "apex" ofthe ROC curve comes to the upper left comer 
of the X-Y plot. Therefore, the higher the sum the greater the area under the 
ROC curve and the better the test. According to Gambino (1991), the 
performance ofdiagnostic tests are characterized as in table 27. 
The ADA test developed has a sum of sensitivity and specificity of 185 
and 182 at the cutoffs of 45.81 and 53 IU/L respectively. It is classified as a 
good test. 
On the other hand, a significant increase in pleural fluid ADA in TB 
versus non-TB pleural fluid but no significant increase in semm ADA is 
observed in TB imply that the origin of ADA elevation in pleural spaces is not 
67 
from leakage ofthe enzyme from the blood to the pleural spaces as a result ofthe 
change in capillary permeability. Instead local production of ADA is more 
likely. Macrophages migrate into the pleural spaces during a cellular immune 





In this study, it is found that pleural fluid total cholesterol level of>1.2 
mmol/L and a pleural fluid lactate dehydrogenase level of >200 U/L is the best 
combination oftests and the optimal cutoffs for identification ofexudate. 
Protein electrophoresis gives qualitative information concerning pleural 
capillary permeability changes that allow high molecular weight molecules to 
pass through the endothelium. This information supplements the quantitative 
information provided by the pleural fluid and semm chemistries. 
A shortcoming of the study is that the number of transudative pleural 
effusion is relatively small. This is attributed to the relative rarity of transudative 
pleural effusion in our hospital setting. More often than not, patients suspected 
of having a transudative effusion due to congestive heart failure are given 
diuretics. The use of diuretic therapy may alter pleural fluid chemistries so that 
their levels resemble that of an exudative pleural effusion (Pillay 1965, Chakko 
et al 1989). It is in this case that exudative range of protein and other analytes 
occurs in patients having a transudative pathology. 
The adenosine deaminase assay optimized is a rapid, sensitive and 
specific diagnostic test for the identification of tuberculous pleurisy. Using a 
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